Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of CN-105 peptide for acute intracerebral hemorrhage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracerebral Hemorrhage

Drugs mentioned

• CN-105 peptide (CN-105)

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Intracerebral Hemorrhage | Phase 2 | Status: UNKNOWN